World Journal of Hepatology最新文献

{"title":"Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.","authors":"Xi-Xi Wang, Chun Yan, Su-Juan Wang, Hong Zhu, Chang-Chun Cao, Li Wu, Shuang Wang, Ji Hu, Hong-Hong Zhang","doi":"10.4254/wjh.v17.i7.109067","DOIUrl":"10.4254/wjh.v17.i7.109067","url":null,"abstract":"<p><strong>Background: </strong>Diabetic gastrointestinal autonomic neuropathy (DGAN) often affects the patients' quality of life. Thus, research on influencing factors of DGAN may promote DGAN prevention and decrease the incidence rate. This study used electrogastrogram (EGG) to assess the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and DGAN.</p><p><strong>Aim: </strong>To analyze the changes of EGG in patients with MASLD and type 2 diabetes mellitus (T2DM), and to elucidate whether ultrasound-diagnosed MASLD is an independent risk factor for diabetic gastric motility disorders (DGMD).</p><p><strong>Methods: </strong>A total of 272 patients with T2DM hospitalized at the Second Affiliated Hospital of Soochow University from December 2020 to December 2021 and the Affiliated Suqian Hospital of Xuzhou Medical University from November 2023 to June 2024 were included in the cross-sectional study. General information, clinical data, and medical history of all study subjects, including name, age, gender, body mass index, and duration of diabetes were collected. Laboratory tests included biochemical parameters, glycosylated hemoglobin (HbA1c), fasting C-peptide, 2h postprandial C-peptide and 25-hydroxyvitamin D [25(OH)D]. EGG, fundus examination and carotid artery ultrasonography were performed and results were recorded. According to the results of EGG, the subjects were divided into the DGMD group and non-DGMD group.</p><p><strong>Results: </strong>The duration of diabetes, fasting blood glucose (FBG), HbA1c, 25(OH)D and the prevalence of MASLD were significantly higher in the DGMD group (<i>P</i> < 0.05). Multiple logistic regression analysis showed that the duration, FBG, 25(OH)D and the presence of MASLD were independent influencing factors.</p><p><strong>Conclusion: </strong>MASLD is strongly associated with an increased incidence of DGMD. Timely treatment of MASLD is effective to prevent diabetic gastroparesis.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"109067"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver and systemic hemodynamics in cirrhotic children.","authors":"Roberto Tambucci, Xavier Stephenne, Aniss Channaoui, Catherine de Magnée","doi":"10.4254/wjh.v17.i7.103179","DOIUrl":"10.4254/wjh.v17.i7.103179","url":null,"abstract":"<p><p>Portal hypertension and cirrhosis are associated with severe hemodynamic changes in hepatic and systemic circulation in the adult population. During cirrhosis progression, circulation becomes hyperdynamic, with cardiac, pulmonary and renal consequences. Cirrhotic adults also present with cirrhotic cardiomyopathy, with systolic and diastolic dysfunction and electrophysiological abnormalities. This article provides an update on normal liver hemodynamics, a brief reminder of the liver and systemic hemodynamics in cirrhotic adults, and a description of liver and systemic hemodynamics in cirrhotic children. This review attempts to clarify whether liver and systemic hemodynamics are altered in cirrhotic children like they are in adults. The characterization of these hemodynamic disturbances could contribute to a better understanding of hepatic and systemic physiopathology in pediatric cirrhosis.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"103179"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing therapeutic vaccines for chronic hepatitis B: Integrating reverse vaccinology and immunoinformatics.","authors":"Patricia Gita Naully, Marselina Irasonia Tan, Korri Elvanita El Khobar, Caecilia H C Sukowati, Ernawati Arifin Giri-Rachman","doi":"10.4254/wjh.v17.i7.107620","DOIUrl":"10.4254/wjh.v17.i7.107620","url":null,"abstract":"<p><p>Current treatments for chronic hepatitis B (CHB) are lifelong, often accompanied by side effects and the risk of drug resistance, highlighting the urgent need for alternative therapies such as therapeutic vaccines. However, challenges such as selecting appropriate antigens and addressing multiple hepatitis B virus (HBV) genotypes hinder the development of these vaccines. One approach to overcoming these challenges is reverse vaccinology (RV) combined with immunoinformatics. RV uses computational methods to identify antigens from pathogen genetic information, including genomic and proteomic data. These methods have helped researchers identify conserved epitopes across bacterial strains or viral species, including multiple HBV genotypes. Computational tools, such as epitope mapping algorithms, molecular docking analysis, molecular dynamics simulations, and immune response simulations, enable key epitope identification, predict vaccine candidates' binding potential to immune cell receptors, and forecast the immune response. Together, these approaches streamline therapeutic vaccine design for CHB, making it faster, more cost-effective, and accurate. This review aims to explore the potential role of RV and immunoinformatics in advancing therapeutic vaccine design for CHB.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107620"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the role of <i>taurine-upregulated gene 1</i> in liver diseases: Mechanisms, clinical relevance, and emerging therapeutic opportunities.","authors":"Thammachanok Boonto, Chaiyaboot Ariyachet","doi":"10.4254/wjh.v17.i7.106795","DOIUrl":"10.4254/wjh.v17.i7.106795","url":null,"abstract":"<p><p>Liver diseases are progressive conditions driven by multiple factors, including molecular regulators such as nonprotein-coding RNAs, which orchestrate genetic and epigenetic processes across various biological levels. Long noncoding RNAs (lncRNAs), RNA molecules longer than 200 nucleotides, have been identified as key modulators in both cancerous and noncancerous liver diseases. Among them, <i>taurine-upregulated gene 1</i> (TUG1), one of the earliest discovered lncRNAs, has emerged as a tumor promoter in hepatocellular carcinoma. Functionally, TUG1 exerts its regulatory effects primarily through microRNA sponging as a competing endogenous RNA while also exhibiting protein-binding capabilities that suggest additional roles in both transcriptional and posttranscriptional regulation. Furthermore, evidence suggests that dysregulation of TUG1 is closely linked to the development and progression of liver diseases. This review explores the key characteristics, mechanisms, and signaling pathways through which TUG1 affects liver disease, offering fresh insights into potential therapeutic directions and new avenues for future TUG1-related research.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106795"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating serum extra spindle pole bodies-like 1 protein <i>vs</i> p53 antibody for hepatitis B virus-related hepatocellular carcinoma diagnosis.","authors":"Yan-Fei Feng, Hui-Kun Zhou, Bo-Bin Hu, Hang Wang, Heng-Kai Liang, Lu Wei, Qing-Mei Li, Tu-Mei Su, Qian-Bing Yin, Ming-Hua Su, Jian-Ning Jiang","doi":"10.4254/wjh.v17.i7.108850","DOIUrl":"10.4254/wjh.v17.i7.108850","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection is a leading cause of global hepatocellular carcinoma (HCC). Conventional biomarkers such as alpha-fetoprotein (AFP) demonstrate suboptimal sensitivity and specificity. Emerging evidence suggests that serum extra spindle pole bodies like 1 (ESPL1) protein and p53 antibody may improve diagnostic accuracy.</p><p><strong>Aim: </strong>To assess and compare the diagnostic performance of serum ESPL1 protein and p53 antibody in HBV-related HCC (HBV-HCC).</p><p><strong>Methods: </strong>This case-control study from the First Affiliated Hospital of Guangxi Medical University enrolled 30 patients with chronic hepatitis B (CHB), 30 with HBV-related liver cirrhosis (HBV-LC), 55 with HBV-HCC, and 30 healthy controls. Serum ESPL1 protein and p53 antibody levels were quantified <i>via</i> ELISA. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, including sensitivity, specificity, and correlation with AFP.</p><p><strong>Results: </strong>Serum ESPL1 protein levels progressively increased across disease stages (CHB: 89.9 ng/L; HBV-LC: 188.83 ng/L; HBV-HCC: 317.63 ng/L), with a significantly higher area under the ROC curve (AUC = 0.917) than either p53 antibody (AUC = 0.725) or AFP (AUC = 0.678). p53 antibody levels were significantly elevated only in the HBV-HCC group. ESPL1 demonstrated superior sensitivity and concordance with histopathological findings. A significant correlation between ESPL1 and p53 antibody levels was observed exclusively in the HBV-HCC group (<i>r</i> = 0.320, <i>P</i> = 0.017), suggesting potential interplay in malignant transformation.</p><p><strong>Conclusion: </strong>Serum ESPL1 protein, a promising biomarker for early HBV-HCC detection, outperforms p53 antibody in diagnostic reliability. Higher ESPL1 levels correlate with increased HCC risk in chronic HBV patients.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"108850"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving therapeutic landscape of primary biliary cholangitis: A review.","authors":"Natalie E Mitchell, Shu-Yen Chan, David Jerez Diaz, Nida Ansari, Junseo Lee, Patrick Twohig","doi":"10.4254/wjh.v17.i7.107223","DOIUrl":"10.4254/wjh.v17.i7.107223","url":null,"abstract":"<p><p>Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive bile duct destruction, leading to fibrosis, cirrhosis, and eventual liver failure. Over the past two decades, significant advancements have paved the way for novel therapeutic strategies. Ursodeoxycholic acid (UDCA) has been the cornerstone of PBC management, improving survival and delaying disease progression in most patients. However, up to 40% of patients demonstrate an inadequate response to UDCA, necessitating additional treatment options. Obeticholic acid (OCA), a farnesoid X receptor agonist, has emerged as a second-line therapy, showing efficacy in reducing alkaline phosphatase levels and improving liver biochemistry. Beyond UDCA and OCA, a new wave of therapeutic agents are reshaping the PBC landscape. These include fibrates, peroxisome proliferator-activated receptor agonists and novel immunomodulatory drugs aimed at reducing autoimmune-mediated liver injury. Bile acid transport inhibitors, anti-fibrotic agents, and gut microbiome-targeted therapies are also under investigation, offering hope for personalized treatment approaches. This review highlights the evolution of PBC therapy, emphasizing the unmet needs of patients with refractory disease and the potential of emerging therapies to improve outcomes. As the therapeutic landscape continues to expand, optimizing treatment strategies through precision medicine holds the promise of transforming the management of PBC.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107223"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis.","authors":"Bo Zang, Jia-Xiu Li, Qi-Xuan Liu, Yuan Yao, Hua Li, Yan Wang, Ji-Gang Wang, Yi-Fei Yang, Rui-Wen Liang, Xin-Ran Xin, Bin Liu","doi":"10.4254/wjh.v17.i7.107666","DOIUrl":"10.4254/wjh.v17.i7.107666","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of primary biliary cholangitis (PBC) remains unclear. Ursodeoxycholic acid (UDCA) is the only first-line clinical treatment, but approximately 40% of patients exhibit a poor response.</p><p><strong>Aim: </strong>To identify novel biomarkers for PBC to predict the efficacy of UDCA and enhance treatment.</p><p><strong>Methods: </strong>Microarray expression profiling datasets were downloaded from the Gene Expression Omnibus and analyzed to identify differentially expressed genes between PBC patients and healthy controls. Immunohistochemistry was performed to validate key genes in liver tissues of the participants. Logistic regression was employed to evaluate prognostic risk factors, receiver operating characteristic curves were used to assess predictive performance, and correlations between key genes and clinicopathological characteristics were analyzed.</p><p><strong>Results: </strong>By bioinformatic analysis, 13 genes primarily associated with the progression of PBC were identified, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) was selected for further investigation. Then expression of TNFAIP3 in PBC patients was significantly elevated compared to healthy controls on immunohistochemistry (<i>P</i> < 0.0001). Multivariate Cox regression analysis indicated that both TNFAIP3 and fatigue were independent risk factors for response to UDCA in PBC patients (<i>P</i> < 0.05). The area under the curve for TNFAIP3 and fatigue were 0.691 and 0.704, respectively, while their combination showed a significantly higher area under the curve of 0.848. The expression of TNFAIP3 was also correlated with age, albumin, total bilirubin, alkaline phosphatase and splenomegaly (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>TNFAIP3 and fatigue are independent risk factors for response to UDCA in Chinese patients with PBC. TNFAIP3 may be a potential biomarker or therapeutic target for PBC. These findings offer new insights into the pathogenesis of PBC.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107666"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the oncogenic role of Rac family small GTPase 3 in hepatocellular carcinoma through multiomics integration.","authors":"Run Liu, Jin-Cheng Li, Shi-De Li, Jian-Di Li, Rong-Quan He, Gang Chen, Zhen-Bo Feng, Jia-Liang Wei","doi":"10.4254/wjh.v17.i7.106151","DOIUrl":"10.4254/wjh.v17.i7.106151","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) remains a lethal malignancy due to its molecular complexity and chemoresistance. Rac family small GTPase 3 (RAC3), a tumorigenic GTPase understudied in HCC, drives recurrence <i>via</i> E2F transcription factor 1 (E2F1)-mediated transcriptional activation. This study integrates multiomics and clustered regularly interspaced short palindromic repeats (CRISPR) screening to delineate RAC3's roles. RAC3 overexpression correlates with advanced HCC and patient age, while its knockout suppresses proliferation. Mechanistically, RAC3 dysregulates cell-cycle checkpoints through E2F1 binding. Pharmacological RAC3 inhibition disrupts tumor growth and synergizes with chemotherapy to overcome resistance.</p><p><strong>Aim: </strong>To explore RAC3's expression, clinical links, and HCC mechanisms <i>via</i> multiomics and functional genomics.</p><p><strong>Methods: </strong>Multiomic integration of The Cancer Genome Atlas (TCGA), Gene Expression Omnibus, and Genotype-Tissue Expression datasets was performed to analyze RAC3 mRNA expression. Immunohistochemistry quantified RAC3 protein in 108 HCC/adjacent tissue pairs. Kaplan-Meier/Cox regression assessed prognostic significance using TCGA data. CRISPR screening validated RAC3's necessity for HCC proliferation. Functional enrichment identified associated pathways; hTFtarget/JASPAR predicted transcription factors, validated <i>via</i> chromatin immunoprecipitation sequencing (ChIP-seq).</p><p><strong>Results: </strong>RAC3 exhibited significant mRNA and protein overexpression in HCC tissues, which was correlated with advanced tumor stages and reduced overall survival rates (hazard ratio = 1.82, 95%CI: 1.31-2.53). Genetic ablation of RAC3 suppressed HCC cell proliferation across 16 cell lines. Pathway analysis revealed RAC3's predominant involvement in cell-cycle regulation, DNA replication, and nucleocytoplasmic transport. Mechanistic investigations identified E2F1 as a pivotal upstream transcriptional regulator, and ChIP-seq analysis validated its direct binding to the RAC3 promoter region. These findings suggest that RAC3 drives HCC progression through E2F1-mediated cell-cycle dysregulation.</p><p><strong>Conclusion: </strong>This study identified RAC3 as a key HCC oncogenic driver; its overexpression links to poor prognosis/resistance. Targeting the RAC3/E2F1 axis offers a new therapy, which highlights RAC3 as a biomarker/target.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106151"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart rate variability in the clinical assessment of patients with chronic liver disease.","authors":"Nicolás Bustos, Flavia Giubergia, Cristóbal Mora, Christian Lara, Álvaro Urzúa, Máximo Cattaneo, Jaime Poniachik, Daniela B Vera, Abraham Ij Gajardo","doi":"10.4254/wjh.v17.i7.106291","DOIUrl":"10.4254/wjh.v17.i7.106291","url":null,"abstract":"<p><p>Autonomic dysfunction (AD) is frequently observed in cirrhotic patients and is associated with poor clinical outcomes and prognoses. Heart rate variability (HRV), a noninvasive tool for assessing autonomic nervous system balance, has been extensively studied in a variety of conditions, including chronic liver disease (CLD); however, no recent reviews have focused on its role in CLD. This article examines the mechanisms of AD in CLD and the foundation for HRV assessment, highlighting its diagnostic, prognostic, and therapeutic applications in CLD, including liver transplantation (LT). Changes in HRV, particularly in patients with cirrhotic complications, and its prognostic significance throughout the natural history of CLD are summarized. We show that HRV is consistently reduced in CLD patients, reflecting AD, and is inversely correlated with liver disease severity. Also, low HRV is associated with complications such as hepatic encephalopathy, ascites, and portal hypertension. Moreover, evidence indicates that reduced HRV is an independent risk factor for mortality and circulatory instability in CLD. Furthermore, treatment with beta-blockers and LT improves HRV, underscoring its potential role in patient management. While further studies are needed, HRV emerges as a promising tool for the comprehensive evaluation and clinical management of patients with CLD, offering insights into disease progression and therapeutic response.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106291"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.","authors":"Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche","doi":"10.4254/wjh.v17.i7.107668","DOIUrl":"10.4254/wjh.v17.i7.107668","url":null,"abstract":"<p><p>The search for reliable biomarkers to predict metabolic dysfunction-associated steatotic liver disease (MASLD) remains a key research focus. Traditional anthropometric parameters, such as triglycerides, glucose, and waist circumference (WC), have proven to be robust tools for diagnosing, stratifying, and predicting health outcomes. These measures facilitate early detection, personalized treatment strategies, and long-term risk assessment in metabolic health. The triglyceride-glucose (TyG) index and related parameters, particularly the TyG-WC index, are gaining recognition as reliable biomarkers for MASLD, with consistently high diagnostic accuracy across diverse populations. The TyG-WC index is associated with MASLD and an increased likelihood of all-cause, cardiovascular, and diabetes-related mortality, highlighting its importance in stratification and patient management. This opinion review summarizes key findings on the TyG-WC index across different MASLD populations and provides nutritional recommendations aimed at reducing this index. The TyG-WC index stands out as a practical and scalable biomarker for identifying and stratifying the risk of MASLD, particularly in resource-limited environments where access to advanced diagnostic tools is restricted. However, before the TyG-WC index can be integrated into routine clinical practice, rigorous, longitudinal studies involving ethnically diverse cohorts must validate its prognostic performance. It should be viewed as a complementary tool within a comprehensive metabolic risk assessment framework, supporting preventive strategies while awaiting formal endorsement in clinical guidelines.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107668"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}